Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02914314 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT02914314 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 26 participants.
The verdict
NCT02914314, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of perampanel during the Maintenance Period of the Core Study following oral suspension administration given as an adjunctive therapy in pediatric participants from 1 month to less than 4 years of age with epilepsy.
Interventions
- DRUG perampanel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-02-20 |
| Est. Completion | 2023-04-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02914314
The ClinicalTrials.gov registry entry for NCT02914314 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which perampanel is the first listed.
NCT02914314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02914314 about?
NCT02914314 is a clinical study titled "Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy". The purpose of this study is to evaluate the pharmacokinetics (PK) of perampanel during the Maintenance Period of the Core Study following oral suspension administration given as an adjunctive therapy in pediatric participants from 1 month to less than 4 years of age with epilepsy.
What is the current status of trial NCT02914314?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2017-02-20. Estimated completion is 2023-04-25.
What interventions are being tested in trial NCT02914314?
The interventions under investigation include: perampanel (DRUG).
Who is sponsoring clinical trial NCT02914314?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.